Full-Time
Senior Clinical Research-Infectious Disease Director
Clinical Research-Infectious Disease
Updated on 9/3/2026
Vir Biotechnology
201-500 employees
Develops monoclonal antibodies for infectious diseases
Compensation Overview
$235.5k - $329.5k/yr
No H1B Sponsorship
San Francisco, CA, USA
In Person
Three days per week on-site in San Francisco.
PharmD, PhD, MD
 Biology & Biotech |
|---|
Get referred to Vir Biotechnology
See people who can refer or advise you
- MD, or PharmD/PhD and 8-10+ years of clinical development experience in the biopharmaceutical industry, with infectious disease or hepatology experience. Other therapeutic areas experience(s) may be considered with strong regulatory submission experience.
- Demonstrated late‑stage/registrational experience, including leadership of or major contribution to Phase III programs, and direct experience supporting at least one BLA (or NDA/MAA) submission in a clinical leadership role required
- Deep familiarity with GCP, ICH guidelines, and global regulatory expectations for registrational trials
- Proven ability to design and interpret complex Phase II/III clinical trials and integrated clinical packages, and to interact effectively with Health Authorities, KOLs, and internal senior leadership.
- Demonstrated experience leading cross‑functional teams
- Lead one of our HDV Phase 3 studies for Clinical Development and support the Clinical Development Sub team Lead
- Execute the late‑stage clinical development plan providing oversight of Phase III studies, incl, including medical monitoring and benefit–risk assessment
- Lead BLA‑enabling activities and clinical components of global regulatory submissions (e.g., BLA, NDA, MAA) and Health Authority interactions
- Contribute to the development and execution of a life cycle management strategy, including but not limited to potential post marketing commitments from a clinical development perspective
- Partner with Regulatory Affairs, Biostatistics, Data Management, and Medical Writing to ensure clinical datasets, narratives, and summaries meet FDA, EMA, and ICH standards for regulatory filings
- Contribute to key clinical and regulatory documents, including protocols, IBs, IND submissions and reports, clinical study reports, and development plans
- Partner with Regulatory Affairs, Biostatistics, Clinical Operations, Safety, Translational Medicine, and Commercial to develop and execute integrated development and registration strategies
- Interpret and integrate clinical data across studies and drive preparation of internal decision documents, integrated analyses, and external publications/presentations
- Build and maintain strong relationships with investigators, KOLs, and advisory boards in infectious diseases
- Ensure adherence to GCP, ICH guidelines, and SOPs, and contribute to continuous improvement of clinical development processes
Vir Biotechnology develops treatments for infectious diseases like hepatitis B, HIV, and influenza by engineering monoclonal antibodies and T cell vaccines. The company uses a proprietary platform enhanced by machine learning and artificial intelligence to identify and optimize human antibodies that can neutralize viruses or stimulate the immune system. Unlike many competitors, Vir integrates these AI capabilities with a broad collaborative network of government and industry partners to rapidly scale its scientific discoveries. Its primary goal is to provide functional cures and preventative medicines for diseases that carry a significant global health burden.
Company Size
201-500
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2016
Get referred to Vir Biotechnology
See people who can refer or advise you
Simplify's Take
What believers are saying
- ECLIPSE 1 top-line hepatitis delta data is due in Q4 2026.
- Phase 1 VIR-5500 expansion began in June 2026, advancing prostate cancer enrollment.
- Q2 2026 collaboration revenue reached $238.9 million, turning Vir profitable.
What critics are saying
- Vir still lacks a permanent CFO and CMO after 2026 leadership turnover.
- VIR-5500's 2027 Phase 3 timeline depends on unproven prostate cancer efficacy.
- ECLIPSE 1 drives Vir's hepatitis D valuation; a miss crushes the stock.
What makes Vir Biotechnology unique
- VIR-5500 is the only dual-masked PSMA-targeting T-cell engager in clinical evaluation.
- Astellas closed a $335 million Vir collaboration on April 16, 2026.
- Vir's second-quarter 2026 cash topped $1.01 billion, funding into second-half 2028.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Comprehensive healthcare coverage
Employer matched 401(k)
Employee stock purchase plan
Childcare assistance
Tuition reimbursement
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%Vir Biotechnology reported an 88% cure rate for hepatitis D virus (HDV) in its Phase 2 SOLSTICE trial, described by a key opinion leader as the best rate in 50 years of HDV treatment. The company completed enrolment in all three registrational ECLIPSE trials, with top-line data from ECLIPSE 1 expected in Q4 2026. Vir strengthened its balance sheet significantly, ending Q2 2026 with approximately $1.01 billion in cash after receiving $315 million from Astellas. This extends its cash runway into the second half of 2028. The company is advancing its oncology pipeline, with VIR-5500 enrolling patients in multiple expansion cohorts. Vir aims to initiate Phase 3 registrational trials as early as next year. The company faces management turnover, actively searching for a new CMO and CFO. R&D expenses increased significantly year-over-year.
Vir Biotechnology (Nasdaq: VIR) reports director exit and 2026 vote outcomes. Filing Impact Filing Sentiment Rhea-AI filing summary. Vir Biotechnology, Inc. reported governance updates and voting results from its 2026 Annual Meeting of Stockholders. Director Saira Ramasastry will step down from the Board and as Audit Committee Chair effective May 26, 2026, citing a business conflict and no disagreement with the company. Robert More was appointed Audit Committee Chair and the Board size was reduced from eight to seven members. Stockholders elected three Class I directors to serve until the 2029 annual meeting, approved on an advisory basis the compensation of named executive officers, and ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. 8-K event classification. 2 items: 5.02, 5.07 Key figures. Shares entitled to vote: 161,234,058 shares Board size after change: 7 directors Say-on-pay votes for: 108,453,963 votes +3 more Key terms. Audit Committee, Annual Meeting of Stockholders, advisory vote on executive compensation, independent registered public accounting firm, +1 more Find StockTitan more easily in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google 05/28/2026 - 06:01 AM Faq. What board change did Vir Biotechnology (VIR) disclose in this 8-K? Vir Biotechnology announced that director Saira Ramasastry will step down from the Board and as Audit Committee Chair effective May 26, 2026, due to a business conflict. The filing states her decision is not related to any disagreement with the company's operations, policies, or practices. Who will chair Vir Biotechnology's (VIR) Audit Committee after the change? The Board appointed Robert More, MBA as Chair of the Audit Committee effective upon Saira Ramasastry's departure on May 26, 2026. At the same time, the Board approved reducing its size from eight to seven members, reflecting this change in composition and committee leadership. How many Vir Biotechnology (VIR) shares were entitled to vote at the 2026 annual meeting? As of the March 31, 2026 record date, 161,234,058 shares of Vir Biotechnology common stock were outstanding and entitled to vote at the 2026 Annual Meeting of Stockholders. These shares formed the basis for quorum and voting calculations on director elections and other proposals. Did Vir Biotechnology (VIR) stockholders approve executive compensation in 2026? Stockholders approved, on an advisory basis, the compensation of Vir Biotechnology's named executive officers. The proposal received 108,453,963 votes for, 11,863,405 votes against, 1,372,563 abstentions, and 16,677,343 broker non-votes, indicating overall support for the company's executive pay program. Which directors were elected at Vir Biotechnology's (VIR) 2026 annual meeting? Stockholders elected three Class I directors: Robert More, Janet Napolitano, and Elliott Sigal. For example, Elliott Sigal received 115,030,681 votes for and 6,659,250 votes withheld, with 16,677,343 broker non-votes. Each will serve until the 2029 Annual Meeting and until a successor is duly elected. Which audit firm did Vir Biotechnology (VIR) stockholders ratify for 2026? Stockholders ratified Ernst & Young LLP as Vir Biotechnology's independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 137,048,756 votes for, 153,836 votes against, and 1,164,682 abstentions, with no broker non-votes reported for this proposal. Filing exhibits & attachments. 4 documents
Superstring Capital Management established a new position in Vir Biotechnology, acquiring 730,548 shares worth approximately $5.82 million during the first quarter of 2026, according to an SEC filing. The position was valued at $6.55 million by quarter-end. Vir shares have surged 99% over the past year to $9.19, significantly outperforming the S&P 500's 28% gain. The commercial-stage biotech company develops immunology-based therapies for infectious diseases including COVID-19, hepatitis B and HIV, though it remains unprofitable with a $442.7 million net loss. The company reported $809.3 million in cash and expects an additional $315 million from its Astellas collaboration. Vir is advancing its pipeline with Phase 2 hepatitis delta data showing 88% of patients achieving undetectable virus levels, and Phase 3 results expected in late 2026.
SB Investment Advisers (UK) Ltd sold 2,168,884 shares of Vir Biotechnology, worth approximately $17.28 million, according to an SEC filing dated 15 May 2026. Despite the sale, Vir remains among the firm's larger healthcare holdings at roughly $98 million, representing 1.3% of assets under management. Vir Biotechnology shares traded at $8.79 as of 15 May 2026, up 93% over the previous year, significantly outperforming the S&P 500's 25% gain. The company has transitioned beyond its pandemic focus, advancing its oncology pipeline including VIR-5500 in partnership with Astellas and its hepatitis delta programme, which showed 77% of patients achieving undetectable virus levels at Week 72. Vir ended the quarter with $809.3 million in cash and investments.
Vir Biotechnology reported disappointing first-quarter results, with revenues falling 100% below analyst predictions and statutory profits turning into a loss of $0.85 per share. The stock dropped 10% to $9.12 following the announcement. Despite the setback, analysts remain cautiously optimistic about the company's future. The consensus forecast from five analysts projects revenues of $249.4 million in 2026, representing a 281% improvement over the past 12 months. Losses per share are expected to narrow 45% to $1.45. The consensus price target held steady at $20.56, with analyst estimates ranging from $16.00 to $30.00. Vir Biotechnology is forecast to achieve 5x annualised revenue growth through 2026, significantly outpacing the industry's projected 22% annual growth rate.